Identification of Patients with Pentosan Polysulfate Sodium-Associated Maculopathy through Screening of the Electronic Medical Record at an Academic Center
Table 2
Detailed clinical information of the 4 identified cases of pentosan polysulfate sodium associated maculopathy. U = unknown and W = white.
Age (years)
67
70
81
74
Race
U
W
W
W
Gender
F
F
F
F
Interval from date of IC diagnosis until now (years)
20
13
6
15
Duration of PPS use (years)
19
10
5
13
PPS daily dose (mg)
400
400
400
378
PPS daily dose by body weight (mg/kg)
5
7
8
7
BMI (kg/m^2)
25
21
21
23
Cumulative PPS exposure to date (g)
2776
1567
812
1794
Age at eye exam
66
69
81
74
Cumulative PPS at time of eye exam (g)
2694
1567
812
1794
Reason for visit
Postoperative visit
Choroidal malignancy
Second opinion for atypical macula findings
Referral for visual field loss
BCVA OD logarithmic
0.3
0
1.9
0.3
Snellen equivalent
20/40
20/20
20/1600
20/40
BCVA OS logarithmic
0.5
0.1
1.9
0.3
Snellen equivalent
20/63
20/25
20/1600
20/40
Tobacco and drug use
Yes (unknown pack-years)
No
Yes (1 pack-year)
No
Comorbidities
Depression, anxiety, and arthritis
Hypertension
Hypertension
Ulcerative colitis postcolectomy 4 years ago, chronic kidney disease not requiring dialysis, anxiety, and hypothyroidism
